Skip to search formSkip to main contentSkip to account menu

SIB 1508Y

Known as: SIB-1508Y 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist
2006
2006
Expedient five-step synthesis of SIB-1508Y from natural nicotine.
Altinicline (SIB-1508Y), an anti-Parkinson's agent, was prepared in five steps from natural nicotine in 32% overall yield via a… 
2006
2006
Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease
  • Neurology
  • 2006
  • Corpus ID: 31720763
This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective α4β2… 
Highly Cited
2000
Highly Cited
2000
Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression
Abstract.Rationale: Epidemiological studies of smokers suggest that there is a link between nicotine and depression. Nonetheless… 
2000
2000
Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist.
Highly Cited
1999
Highly Cited
1999
Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Monkeys that receive chronic low-dose 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) administration have difficulty… 
Highly Cited
1998
Highly Cited
1998
Effects of SIB‐1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys
The potential antiparkinsonian effects of the centrally acting, subtype‐selective neuronal nicotinic acetylcholine receptor… 
Review
1998
Review
1998
The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.
Review
1998
Review
1998
Effects of the nicotinic acetylcholine receptor agonist SIB‐1508Y on object retrieval performance in MPTP‐Treated monkeys: Comparison with levodopa treatment
This study assessed the relative potencies of levodopa/benserazide and the nicotinic acetylcholine receptor agonist SIB‐1508Y on… 
Highly Cited
1996
Highly Cited
1996
(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License